GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback